Figure 1.
![Figure 1. PFS. Kaplan-Meier estimates of PFS of (A) all patients and subgroups stratified by: (B) TP53 aberration (absent vs present), (C) prior treatment (RR CLL vs TN), (D) Rai stage (I/II vs III/IV), (E) B2M (≤4 mg/L vs >4 mg/L), and (F) IGHV mutational status (mutated IGHV [M] vs unmutated IGHV [U]). Among patients with TP53 aberration (n = 53), subgroups are further divided by: (G) prior treatment (RR vs TN), (H) Rai stage (I/II vs III/IV), and (I) B2M (≤4 mg/L vs >4 mg/L).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/129/11/10.1182_blood-2016-06-719294/4/blood719294f1.jpeg?Expires=1726817730&Signature=x1RmMRIo8CPZfSumk5dYsD8hgYOqEv7XoJ4HHyMtJ0hoZMJOylyPc-w-yst1dSW-4Zt3ZcCgznCac4Lawe2MRujPyUD2~eVnjWFd493PsQxQxgUTT4lomo~iWps-LxmCvncKb~NkPhqlwPROthtfrWQ6vOH3OoUzD0R4LNiiCJY1ayaBb58finbfCwMN0BfnWs6toP1iaU0FUU9Bwe3t5btS0FIO4MSnJ6055Q8~b4yc64ZzqGkPG6UGWVMK0ftjxsEFG41PBOrvU7CD5MG04l2LZKewpweEo~SZ6tPJZYirqARHCbCck-4g8EBVpXH1lD-28hjI9Knqg4bAhpfPXQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PFS. Kaplan-Meier estimates of PFS of (A) all patients and subgroups stratified by: (B) TP53 aberration (absent vs present), (C) prior treatment (RR CLL vs TN), (D) Rai stage (I/II vs III/IV), (E) B2M (≤4 mg/L vs >4 mg/L), and (F) IGHV mutational status (mutated IGHV [M] vs unmutated IGHV [U]). Among patients with TP53 aberration (n = 53), subgroups are further divided by: (G) prior treatment (RR vs TN), (H) Rai stage (I/II vs III/IV), and (I) B2M (≤4 mg/L vs >4 mg/L).
